Noclaud (Cilostazol)

Cilostazol is indicated for conditions affecting peripheral circulation and walking ability.

• Intermittent claudication: improves pain‑free walking distance in patients with peripheral arterial disease.
• Peripheral arterial disease: reduces limb ischemic symptoms and enhances functional capacity.
• Symptomatic peripheral vascular disease: alleviates leg pain and improves exercise tolerance.

• Cilostazol inhibits phosphodiesterase‑3, leading to increased intracellular cyclic AMP in vascular smooth muscle and platelets. Elevated cAMP causes vasodilation, improves blood flow to the limbs, and suppresses platelet aggregation, thereby addressing the reduced perfusion that underlies intermittent claudication and related peripheral vascular conditions.

Cilostazol may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Diarrhea: loose stools that may resolve with continued therapy.
• Dizziness: sensation of light‑headedness, especially on standing.
• Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects

• Thrombocytopenia: significant reduction in platelet count requiring monitoring.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Rhabdomyolysis: muscle breakdown with potential kidney injury.

Cilostazol requires careful consideration of patient‑specific factors before prescribing.

• Heart failure: avoid use in patients with symptomatic heart failure.
• Bleeding risk: monitor patients with a history of bleeding or on anticoagulants.
• Hepatic impairment: use with caution in moderate to severe liver disease.
• Renal impairment: dose adjustment may be needed in severe renal dysfunction.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Store at room temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Cilostazol can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cilostazol levels and toxicity.
• Anticoagulants (e.g., warfarin): heightened risk of bleeding.
• Other antiplatelet agents (e.g., clopidogrel, aspirin): additive antithrombotic effect increasing hemorrhage risk.

Moderate Interactions (Monitor Closely)

• CYP2C19 inhibitors (e.g., omeprazole, fluvoxamine): may modestly raise cilostazol concentrations.
• Antihypertensive drugs (e.g., beta‑blockers, ACE inhibitors): potential additive blood‑pressure lowering effect.